Towards translational therapies for multiple system atrophy

Progress in Neurobiology

Volumn 118, Issue , 2014, Pages 19-35

  Kuzdas Wood, Daniela ^a   Stefanova, Nadia ^a   Jellinger, Kurt A ^b   Seppi, Klaus ^a   Schlossmacher, Michael G ^c   Poewe, Werner ^a   Wenning, Gregor K ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Alpha synuclein; Multiple system atrophy; Neurodegeneration; Olivopontocerebellar atrophy; Striatonigral degeneration

Indexed keywords

ALPHA SYNUCLEIN; AMITRIPTYLINE; FLUOXETINE; HUMAN GROWTH HORMONE; IMMUNOGLOBULIN; MINOCYCLINE; NEUROTOXIN; NOCODAZOLE; OLANZAPINE; RASAGILINE; RIFAMPICIN; RILUZOLE; TERAZOSIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

CELL LOSS; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; MESENCHYMAL STEM CELL; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; REVIEW; SHY DRAGER SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPATHETIC INNERVATION; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; METABOLISM; MITOCHONDRION; MULTIPLE SYSTEM ATROPHY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; MITOCHONDRIA; MULTIPLE SYSTEM ATROPHY; OXIDATIVE STRESS;

EID: 84901821738     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2014.02.007     Document Type: Review

References (215)

1. Abe H., Yagishita S., Amano N., Iwabuchi K., Hasegawa K., Kowa K. Argyrophilic glial intracytoplasmic inclusions in multiple system atrophy: immunocytochemical and ultrastructural study. Acta Neuropathol. 1992, 84:273-277.
2. Aerts M.B., Esselink R.A., Abdo W.F., Bloem B.R., Verbeek M.M. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging 2012, 33:430.e1-430.e3.
3. Ahmed Z., Asi Y.T., Lees A.J., Revesz T., Holton J.L. Identification and quantification of oligodendrocyte precursor cells in multiple system atrophy, progressive supranuclear palsy and Parkinson's disease. Brain Pathol. 2013, 23:263-273.
4. Akundi R.S., Huang Z., Eason J., Pandya J.D., Zhi L., Cass W.A., Sullivan P.G., Bueler H. Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. PLoS ONE 2011, 6:e16038.
5. Al-Chalabi A., Durr A., Wood N.W., Parkinson M.H., Camuzat A., Hulot J.S., Morrison K.E., Renton A., Sussmuth S.D., Landwehrmeyer B.G., Ludolph A., Agid Y., Brice A., Leigh P.N., Bensimon G. Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS ONE 2009, 4:e7114.
6. Angot E., Steiner J.A., Hansen C., Li J.Y., Brundin P. Are synucleinopathies prion-like disorders?. Lancet Neurol. 2010, 9:1128-1138.
7. Angot E., Steiner J.A., Lema Tome C.M., Ekstrom P., Mattsson B., Bjorklund A., Brundin P. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS ONE 2012, 7:e39465.
8. Bartels A.L., Willemsen A.T., Doorduin J., de Vries E.F., Dierckx R.A., Leenders K.L. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?. Parkinsonism Relat. Disord. 2010, 16:57-59.
9. Benarroch E.E., Smithson I.L., Low P.A., Parisi J.E. Depletion of catecholaminergic neurons of the rostral ventrolateral medulla in multiple systems atrophy with autonomic failure. Ann. Neurol. 1998, 43:156-163.
10. Benarroch E.E. New findings on the neuropathology of multiple system atrophy. Auton. Neurosci. 2002, 96:59-62.
11. Benarroch E.E. Brainstem in multiple system atrophy: clinicopathological correlations. Cell. Mol. Neurobiol. 2003, 23:519-526.
12. Benarroch E.E., Schmeichel A.M., Sandroni P., Low P.A., Parisi J.E. Differential involvement of hypothalamic vasopressin neurons in multiple system atrophy. Brain 2006, 129:2688-2696.
13. Bensimon G., Ludolph A., Agid Y., Vidailhet M., Payan C., Leigh P.N. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009, 132:156-171.
14. Beraud D., Hathaway H.A., Trecki J., Chasovskikh S., Johnson D.A., Johnson J.A., Federoff H.J., Shimoji M., Mhyre T.R., Maguire-Zeiss K.A. Microglial activation and antioxidant responses induced by the Parkinson's disease protein alpha-synuclein. J. Neuroimmune Pharmacol. 2013, 8:94-117.
15. Bidinosti M., Shimshek D.R., Mollenhauer B., Marcellin D., Schweizer T., Lotz G.P., Schlossmacher M.G., Weiss A. Novel one-step immunoassays to quantify alpha-synuclein: applications for biomarker development and high-throughput screening. J. Biol. Chem. 2012, 287:33691-33705.
16. Borlongan C.V., Koutouzis T.K., Randall T.S., Freeman T.B., Cahill D.W., Sanberg P.R. Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats. Brain Res. Bull. 1995, 36:549-556.
17. Boudes M., Uvin P., Pinto S., Voets T., Fowler C.J., Wenning G.K., De Ridder D., Stefanova N. Bladder dysfunction in a transgenic mouse model of multiple system atrophy. Mov. Disord. 2013, 28:347-355.
18. Brundin P., Li J.Y., Holton J.L., Lindvall O., Revesz T. Research in motion: the enigma of Parkinson's disease pathology spread. Nat. Rev. Neurosci. 2008, 9:741-745.
19. Burn D.J., Jaros E. Multiple system atrophy: cellular and molecular pathology. Mol. Pathol. 2001, 54:419-426.
20. Burre J., Vivona S., Diao J., Sharma M., Brunger A.T., Sudhof T.C. Properties of native brain alpha-synuclein. Nature 2013, 498:E4-E6. discussion E6-E7.
21. Choi C., Park J.Y., Lee J., Lim J.H., Shin E.C., Ahn Y.S., Kim C.H., Kim S.J., Kim J.D., Choi I.S., Choi I.H. Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma. J. Immunol. 1999, 162:1889-1895.
22. Colton C., Wilcock D.M. Assessing activation states in microglia. CNS Neurol. Disord. Drug Targets 2010, 9:174-191.
23. Constantinescu R., Mondello S. Cerebrospinal fluid biomarker candidates for parkinsonian disorders. Front. Neurol. 2012, 3:187.
24. Desplats P., Lee H.J., Bae E.J., Patrick C., Rockenstein E., Crews L., Spencer B., Masliah E., Lee S.J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13010-13015.
25. Diguet E., Fernagut P.O., Scherfler C., Wenning G., Tison F. Effects of riluzole on combined MPTP+3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice. J. Neural Transm. 2005, 112:613-631.
26. Dodel R., Spottke A., Gerhard A., Reuss A., Reinecker S., Schimke N., Trenkwalder C., Sixel-Doring F., Herting B., Kamm C., Gasser T., Sawires M., Geser F., Kollensperger M., Seppi K., Kloss M., Krause M., Daniels C., Deuschl G., Bottger S., Naumann M., Lipp A., Gruber D., Kupsch A., Du Y., Turkheimer F., Brooks D.J., Klockgether T., Poewe W., Wenning G., Schade-Brittinger C., Oertel W.H., Eggert K. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov. Disord. 2010, 25:97-107.
27. Duda J.E., Giasson B.I., Chen Q., Gur T.L., Hurtig H.I., Stern M.B., Gollomp S.M., Ischiropoulos H., Lee V.M., Trojanowski J.Q. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am. J. Pathol. 2000, 157:1439-1445.
28. Duda J.E., Giasson B.I., Gur T.L., Montine T.J., Robertson D., Biaggioni I., Hurtig H.I., Stern M.B., Gollomp S.M., Grossman M., Lee V.M., Trojanowski J.Q. Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J. Neuropathol. Exp. Neurol. 2000, 59:830-841.
29. Eberling J.L., Dave K.D., Frasier M.A. Alpha-synuclein imaging: a critical need for Parkinson's disease research. J. Parkinson's Dis. 2013, 3:565-567.
30. Fellner L., Jellinger K.A., Wenning G.K., Stefanova N. Glial dysfunction in the pathogenesis of alpha-synucleinopathies: emerging concepts. Acta Neuropathol. 2011, 121:675-693.
31. Fellner L., Stefanova N. The role of glia in alpha-synucleinopathies. Mol. Neurobiol. 2012, 47:575-586.
32. Fellner L., Irschick R., Schanda K., Reindl M., Klimaschewski L., Poewe W., Wenning G.K., Stefanova N. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 2013, 61:349-360.
33. Fernagut P.O., Diguet E., Stefanova N., Biran M., Wenning G.K., Canioni P., Bioulac B., Tison F. Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Neuroscience 2002, 114:1005-1017.
34. Fernagut P.O., Diguet E., Bioulac B., Tison F. MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration. Exp. Neurol. 2004, 185:47-62.
35. Flabeau O., Meissner W.G., Ozier A., Berger P., Tison F., Fernagut P.O. Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy. Mov. Disord. 2014.
36. Foulds P.G., Yokota O., Thurston A., Davidson Y., Ahmed Z., Holton J., Thompson J.C., Akiyama H., Arai T., Hasegawa M., Gerhard A., Allsop D., Mann D.M. Post mortem cerebrospinal fluid alpha-synuclein levels are raised in multiple system atrophy and distinguish this from the other alpha-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiol. Dis. 2012, 45:188-195.
37. Frost B., Diamond M.I. Prion-like mechanisms in neurodegenerative diseases. Nat. Rev. Neurosci. 2010, 11:155-159.
38. Fuchs J., Nilsson C., Kachergus J., Munz M., Larsson E.M., Schule B., Langston J.W., Middleton F.A., Ross O.A., Hulihan M., Gasser T., Farrer M.J. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007, 68:916-922.
39. Gai W.P., Pountney D.L., Power J.H., Li Q.X., Culvenor J.G., McLean C.A., Jensen P.H., Blumbergs P.C. Alpha-synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy. Exp. Neurol. 2003, 181:68-78.
40. Ghorayeb I., Puschban Z., Fernagut P.O., Scherfler C., Rouland R., Wenning G.K., Tison F. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration. Exp. Neurol. 2001, 167:133-147.
41. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
42. Giasson B.I., Mabon M.E., Duda J.E., Montine T.J., Robertson D., Hurtig H.I., Lee V.M., Trojanowski J.Q. Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy. Acta Neuropathol. 2003, 106:243-250.
43. Gilman S., Low P., Quinn N., Albanese A., Ben-Shlomo Y., Fowler C., Kaufmann H., Klockgether T., Lang A., Lantos P., Litvan I., Mathias C., Oliver E., Robertson D., Schatz I., Wenning G. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin. Auton. Res. 1998, 8:359-362.
44. Gilman S., Wenning G.K., Low P.A., Brooks D.J., Mathias C.J., Trojanowski J.Q., Wood N.W., Colosimo C., Durr A., Fowler C.J., Kaufmann H., Klockgether T., Lees A., Poewe W., Quinn N., Revesz T., Robertson D., Sandroni P., Seppi K., Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71:670-676.
45. Gitler A.D., Shorter J. Prime time for alpha-synuclein. J. Neurosci. 2007, 27:2433-2434.
46. Hall S., Ohrfelt A., Constantinescu R., Andreasson U., Surova Y., Bostrom F., Nilsson C., Hakan W., Decraemer H., Nagga K., Minthon L., Londos E., Vanmechelen E., Holmberg B., Zetterberg H., Blennow K., Hansson O. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol. 2012, 69:1445-1452.
47. Hanna P.A., Jankovic J., Kirkpatrick J.B. Multiple system atrophy: the putative causative role of environmental toxins. Arch. Neurol. 1999, 56:90-94.
48. Hansen C., Angot E., Bergstrom A.L., Steiner J.A., Pieri L., Paul G., Outeiro T.F., Melki R., Kallunki P., Fog K., Li J.Y., Brundin P. Alpha-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 2011, 121:715-725.
49. Hara K., Momose Y., Tokiguchi S., Shimohata M., Terajima K., Onodera O., Kakita A., Yamada M., Takahashi H., Hirasawa M., Mizuno Y., Ogata K., Goto J., Kanazawa I., Nishizawa M., Tsuji S. Multiplex families with multiple system atrophy. Arch. Neurol. 2007, 64:545-551.
50. Harry G.J., Kraft A.D. Microglia in the developing brain: a potential target with lifetime effects. Neurotoxicology 2012, 33:191-206.
51. Hasegawa T., Baba T., Kobayashi M., Konno M., Sugeno N., Kikuchi A., Itoyama Y., Takeda A. Role of TPPP/p25 on alpha-synuclein-mediated oligodendroglial degeneration and the protective effect of SIRT2 inhibition in a cellular model of multiple system atrophy. Neurochem. Int. 2010, 57:857-866.
52. Holmberg B., Johansson J.O., Poewe W., Wenning G., Quinn N.P., Mathias C., Tolosa E., Cardozo A., Dizdar N., Rascol O., Slaoui T. Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov. Disord. 2007, 22:1138-1144.
53. Hovelmeyer N., Hao Z., Kranidioti K., Kassiotis G., Buch T., Frommer F., von Hoch L., Kramer D., Minichiello L., Kollias G., Lassmann H., Waisman A. Apoptosis of oligodendrocytes via Fas and TNF-R1 is a key event in the induction of experimental autoimmune encephalomyelitis. J. Immunol. 2005, 175:5875-5884.
54. Huang Y., Song Y.J., Murphy K., Holton J.L., Lashley T., Revesz T., Gai W.P., Halliday G.M. LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. Acta Neuropathol. 2008, 116:639-646.
55. Inoue M., Yagishita S., Ryo M., Hasegawa K., Amano N., Matsushita M. The distribution and dynamic density of oligodendroglial cytoplasmic inclusions (GCIs) in multiple system atrophy: a correlation between the density of GCIs and the degree of involvement of striatonigral and olivopontocerebellar systems. Acta Neuropathol. 1997, 93:585-591.
56. Ito H., Kusaka H., Matsumoto S., Imai T. Striatal efferent involvement and its correlation to levodopa efficacy in patients with multiple system atrophy. Neurology 1996, 47:1291-1299.
57. Jecmenica-Lukic M., Poewe W., Tolosa E., Wenning G.K. Premotor signs and symptoms of multiple system atrophy. Lancet Neurol. 2012, 11:361-368.
58. Jellinger K.A., Lantos P.L. Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update. Acta Neuropathol. 2010, 119:657-667.
59. Jellinger K.A. Neuropathology of movement disorders. Youman's Neurological Surgery 2011, 871-898. Elsevier-Saunders. 6th ed. H.R. Winn (Ed.).
60. Jellinger K.A. The role of alpha-synuclein in neurodegeneration - an update. Transl. Neurosci. 2012, 3:75-122.
61. Jin H., Ishikawa K., Tsunemi T., Ishiguro T., Amino T., Mizusawa H. Analyses of copy number and mRNA expression level of the alpha-synuclein gene in multiple system atrophy. J. Med. Dent. Sci. 2008, 55:145-153.
62. Johnson D.A., Andrews G.K., Xu W., Johnson J.A. Activation of the antioxidant response element in primary cortical neuronal cultures derived from transgenic reporter mice. J. Neurochem. 2002, 81:1233-1241.
63. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Spooren W., Fuss B., Mallon B., Macklin W.B., Fujiwara H., Hasegawa M., Iwatsubo T., Kretzschmar H.A., Haass C. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep. 2002, 3:583-588.
64. Kaindlstorfer C., Garcia J., Winkler C., Wenning G.K., Nikkhah G., Dobrossy M.D. Behavioral and histological analysis of a partial double-lesion model of Parkinson-variant multiple system atrophy. J. Neurosci. Res. 2012, 90:1284-1295.
65. Kato S., Oda M., Hayashi H., Shimizu T., Hayashi M., Kawata A., Tanabe H. Decrease of medullary catecholaminergic neurons in multiple system atrophy and Parkinson's disease and their preservation in amyotrophic lateral sclerosis. J. Neurol. Sci. 1995, 132:216-221.
66. Kaufmann H. Multiple system atrophy. Curr. Opin. Neurol. 1998, 11:351-355.
67. Kawamoto Y., Akiguchi I., Shirakashi Y., Honjo Y., Tomimoto H., Takahashi R., Budka H. Accumulation of Hsc70 and Hsp70 in glial cytoplasmic inclusions in patients with multiple system atrophy. Brain Res. 2007, 1136:219-227.
68. Kiely A.P., Asi Y.T., Kara E., Limousin P., Ling H., Lewis P., Proukakis C., Quinn N., Lees A.J., Hardy J., Revesz T., Houlden H., Holton J.L. Alpha-synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. Acta Neuropathol. 2013, 125:753-769.
69. Klegeris A., Pelech S., Giasson B.I., Maguire J., Zhang H., McGeer E.G., McGeer P.L. Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol. Aging 2008, 29:739-752.
70. Kollensperger M., Stampfer-Kountchev M., Seppi K., Geser F., Frick C., Del Sorbo F., Albanese A., Gurevich T., Giladi N., Djaldetti R., Schrag A., Low P.A., Mathias C.J., Poewe W., Wenning G.K. Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. Eur. J. Neurol. 2007, 14:66-72.
71. Kollensperger M., Stefanova N., Reindl M., Poewe W., Wenning G.K. Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy. Mov. Disord. 2007, 22:353-358.
72. Kollensperger M., Stefanova N., Pallua A., Puschban Z., Dechant G., Hainzer M., Reindl M., Poewe W., Nikkhah G., Wenning G.K. Striatal transplantation in a rodent model of multiple system atrophy: effects on l-dopa response. J. Neurosci. Res. 2009, 87:1679-1685.
73. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 2008, 14:504-506.
74. Kovacs G.G., Laszlo L., Kovacs J., Jensen P.H., Lindersson E., Botond G., Molnar T., Perczel A., Hudecz F., Mezo G., Erdei A., Tirian L., Lehotzky A., Gelpi E., Budka H., Ovadi J. Natively unfolded tubulin polymerization promoting protein TPPP/p25 is a common marker of alpha-synucleinopathies. Neurobiol. Dis. 2004, 17:155-162.
75. Kragh C.L., Lund L.B., Febbraro F., Hansen H.D., Gai W.P., El-Agnaf O., Richter-Landsberg C., Jensen P.H. Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J. Biol. Chem. 2009, 284:10211-10222.
76. Kragh C.L., Fillon G., Gysbers A., Hansen H.D., Neumann M., Richter-Landsberg C., Haass C., Zalc B., Lubetzki C., Gai W.P., Halliday G.M., Kahle P.J., Jensen P.H. FAS-dependent cell death in alpha-synuclein transgenic oligodendrocyte models of multiple system atrophy. PLoS ONE 2013, 8:e55243.
77. Krismer F., Wenning G.K., Li Y., Poewe W., Stefanova N. Intact olfaction in a mouse model of multiple system atrophy. PLoS One 2013, 8. e64625.
78. Kunieda T., Zuscik M.J., Boongird A., Perez D.M., Luders H.O., Najm I.M. Systemic overexpression of the alpha 1B-adrenergic receptor in mice: an animal model of epilepsy. Epilepsia 2002, 43:1324-1329.
79. Kuzdas D., Stemberger S., Gaburro S., Stefanova N., Singewald N., Wenning G.K. Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: experimental evidence. Exp. Neurol. 2013, 247:531-536.
80. Langerveld A.J., Mihalko D., DeLong C., Walburn J., Ide C.F. Gene expression changes in postmortem tissue from the rostral pons of multiple system atrophy patients. Mov. Disord. 2007, 22:766-777.
81. Lastres-Becker I., Ulusoy A., Innamorato N.G., Sahin G., Rabano A., Kirik D., Cuadrado A. Alpha-synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Hum. Mol. Genet. 2012, 21:3173-3192.
82. Lee H.J., Suk J.E., Bae E.J., Lee S.J. Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem. Biophys. Res. Commun. 2008, 372:423-428.
83. Lee H.J., Suk J.E., Patrick C., Bae E.J., Cho J.H., Rho S., Hwang D., Masliah E., Lee S.J. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 2010, 285:9262-9272.
84. Lee J.Y., Koga H., Kawaguchi Y., Tang W., Wong E., Gao Y.S., Pandey U.B., Kaushik S., Tresse E., Lu J., Taylor J.P., Cuervo A.M., Yao T.P. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J. 2010, 29:969-980.
85. Lee P., Lee J., Kim H., Song S., Lee H., Nam H., Cheong J., Jeong Y., Park H., Kim D., Nam C., Lee J., Kim H., Sohn Y. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann. Neurol. 2012, 72:32-40.
86. Lee P.H., Kim J.W., Bang O.Y., Ahn Y.H., Joo I.S., Huh K. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin. Pharmacol. Ther. 2008, 83:723-730.
87. Lee S.J., Desplats P., Sigurdson C., Tsigelny I., Masliah E. Cell-to-cell transmission of non-prion protein aggregates. Nat. Rev. Neurol. 2010, 6:702-706.
88. Lee S.J., Lim H.S., Masliah E., Lee H.J. Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci. Res. 2011, 70:339-348.
89. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
90. Lindersson E., Lundvig D., Petersen C., Madsen P., Nyengaard J.R., Hojrup P., Moos T., Otzen D., Gai W.P., Blumbergs P.C., Jensen P.H. p25alpha stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. J. Biol. Chem. 2005, 280:5703-5715.
91. Lindvall O., Kokaia Z. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. Trends Pharmacol. Sci. 2009, 30:260-267.
92. Lindvall O., Kokaia Z. Stem cells in human neurodegenerative disorders - time for clinical translation?. J. Clin. Invest. 2010, 120:29-40.
93. Low P.A., Gilman S. Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective?. Ann. Neurol. 2012, 72:4-5.
94. Low P.A., Robertson D., Gilman S., Kaufmann H., Singer W., Biaggioni I., Freeman R., Perlman S., Hauser R.A., Cheshire W., Lessig S., Vernino S., Mandrekar J., Dupont W.D., Chelimsky T., Galpern W.R. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014, 13:268-275.
95. Luk K.C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J.Q., Lee V.M. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338:949-953.
96. Lull M.E., Block M.L. Microglial activation and chronic neurodegeneration. Neurotherapeutics: J. Am. Soc. Exp. Neurother. 2010, 7:354-365.
97. Luo X.G., Chen S.D. The changing phenotype of microglia from homeostasis to disease. Transl. Neurodegener. 2012, 1:9.
98. Mahlknecht P., Schocke M., Seppi K. Differential diagnosis of parkinsonian syndromes using MRI. Der. Nervenarzt. 2010, 81:1168-1179.
99. Mahlknecht P., Stockner H., Kiechl S., Willeit J., Rastner V., Gasperi A., Rungger G., Poewe W., Seppi K. Is transcranial sonography useful to distinguish drug-induced parkinsonism from Parkinson's disease?. Mov. Disord. 2012, 27:1194-1196.
100. Masliah E., Rockenstein E., Adame A., Alford M., Crews L., Hashimoto M., Seubert P., Lee M., Goldstein J., Chilcote T., Games D., Schenk D. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005, 46:857-868.
101. Masliah E., Rockenstein E., Mante M., Crews L., Spencer B., Adame A., Patrick C., Trejo M., Ubhi K., Rohn T.T., Mueller-Steiner S., Seubert P., Barbour R., McConlogue L., Buttini M., Games D., Schenk D. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 2011, 6:e19338.
102. Matsuo A., Akiguchi I., Lee G.C., McGeer E.G., McGeer P.L., Kimura J. Myelin degeneration in multiple system atrophy detected by unique antibodies. Am. J. Pathol. 1998, 153:735-744.
103. May S., Gilman S., Sowell B.B., Thomas R.G., Stern M.B., Colcher A., Tanner C.M., Huang N., Novak P., Reich S.G., Jankovic J., Ondo W.G., Low P.A., Sandroni P., Lipp A., Marshall F.J., Wooten F., Shults C.W. Potential outcome measures and trial design issues for multiple system atrophy. Mov. Disord. 2007, 22:2371-2377.
104. McCann H., Stevens C.H., Cartwright H., Halliday G.M. Alpha-synucleinopathy phenotypes. Parkinsonism Relat. Disord. 2014, 20(Suppl. 1):S62-S67.
105. McCoy M.K., Cookson M.R. DJ-1 regulation of mitochondrial function and autophagy through oxidative stress. Autophagy 2011, 7:531-532.
106. Meijer F.J., Bloem B.R., Mahlknecht P., Seppi K., Goraj B. Update on diffusion MRI in Parkinson's disease and atypical parkinsonism. J. Neurol. Sci. 2013, 332:21-29.
107. Miki Y., Mori F., Tanji K., Kakita A., Takahashi H., Wakabayashi K. Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions. Neuropathology 2011, 31:561-568.
108. Miller D.W., Johnson J.M., Solano S.M., Hollingsworth Z.R., Standaert D.G., Young A.B. Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J. Neural Transm. 2005, 112:1613-1624.
109. Mollenhauer B., El-Agnaf O.M., Marcus K., Trenkwalder C., Schlossmacher M.G. Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomarkers Med. 2010, 4:683-699.
110. Mollenhauer B., Locascio J.J., Schulz-Schaeffer W., Sixel-Doring F., Trenkwalder C., Schlossmacher M.G. Alpha-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011, 10:230-240.
111. Mollenhauer B., Trautmann E., Otte B., Ng J., Spreer A., Lange P., Sixel-Doring F., Hakimi M., Vonsattel J.P., Nussbaum R., Trenkwalder C., Schlossmacher M.G. Alpha-synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J. Neural Transm. 2012, 119:739-746.
112. Murphy D.D., Rueter S.M., Trojanowski J.Q., Lee V.M. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 2000, 20:3214-3220.
113. Nakayama K., Suzuki Y., Yazawa I. Microtubule depolymerization suppresses alpha-synuclein accumulation in a mouse model of multiple system atrophy. Am. J. Pathol. 2009, 174:1471-1480.
114. Nakayama K., Suzuki Y., Yazawa I. Binding of neuronal alpha-synuclein to beta-III tubulin and accumulation in a model of multiple system atrophy. Biochem. Biophys. Res. Commun. 2012, 417:1170-1175.
115. Nakazato Y., Yamazaki H., Hirato J., Ishida Y., Yamaguchi H. Oligodendroglial microtubular tangles in olivopontocerebellar atrophy. J. Neuropathol. Exp. Neurol. 1990, 49:521-530.
116. NINDS NET-PD Investigators A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin. Neuropharmacol. 2008, 31:141-150.
117. Nishie M., Mori F., Fujiwara H., Hasegawa M., Yoshimoto M., Iwatsubo T., Takahashi H., Wakabayashi K. Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol. 2004, 107:292-298.
118. Nishie M., Mori F., Yoshimoto M., Takahashi H., Wakabayashi K. A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy. Neuropathol. Appl. Neurobiol. 2004, 30:546-554.
119. Novak P., Williams A., Ravin P., Zurkiya O., Abduljalil A., Novak V. Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol. 2012, 12:131.
120. Orimo S., Uchihara T., Nakamura A., Mori F., Kakita A., Wakabayashi K., Takahashi H. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 2008, 131:642-650.
121. Osaki Y., Ben-Shlomo Y., Lees A.J., Wenning G.K., Quinn N.P. A validation exercise on the new consensus criteria for multiple system atrophy. Mov. Disord. 2009, 24:2272-2276.
122. Ovadi J., Orosz F. An unstructured protein with destructive potential: TPPP/p25 in neurodegeneration. Bioessays 2009, 31:676-686.
123. Ozawa T., Okuizumi K., Ikeuchi T., Wakabayashi K., Takahashi H., Tsuji S. Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. Acta Neuropathol. 2001, 102:188-190.
124. Ozawa T., Paviour D., Quinn N.P., Josephs K.A., Sangha H., Kilford L., Healy D.G., Wood N.W., Lees A.J., Holton J.L., Revesz T. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 2004, 127:2657-2671.
125. Ozawa T. Morphological substrate of autonomic failure and neurohormonal dysfunction in multiple system atrophy: impact on determining phenotype spectrum. Acta Neuropathol. 2007, 114:201-211.
126. Papay R., Zuscik M.J., Ross S.A., Yun J., McCune D.F., Gonzalez-Cabrera P., Gaivin R., Drazba J., Perez D.M. Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation. J. Neurochem. 2002, 83:623-634.
127. Papp M.I., Kahn J.E., Lantos P.L. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J. Neurol. Sci. 1989, 94:79-100.
128. Papp M.I., Lantos P.L. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994, 117(Pt 2):235-243.
129. Park H.J., Bang G., Lee B.R., Kim H.O., Lee P.H. Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy parkinsonism. Cell Transpl. 2011, 20:827-835.
130. Pfisterer U., Kirkeby A., Torper O., Wood J., Nelander J., Dufour A., Bjorklund A., Lindvall O., Jakobsson J., Parmar M. Direct conversion of human fibroblasts to dopaminergic neurons. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:10343-10348.
131. Piao Y.S., Hayashi S., Hasegawa M., Wakabayashi K., Yamada M., Yoshimoto M., Ishikawa A., Iwatsubo T., Takahashi H. Co-localization of alpha-synuclein and phosphorylated tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration. Acta Neuropathol. 2001, 101:285-293.
132. Pizza V., Agresta A., D'Acunto C.W., Festa M., Capasso A. Neuroinflamm-aging and neurodegenerative diseases: an overview. CNS Neurol. Disord. Drug Targets 2011, 10:621-634.
133. Poewe W., Barone P., Gliadi N., Gilman S., Low P.A., Sampaio C. A randomized, placebo-controlled clinical trial to assess the effects of rasagiline in patients with multiple system atrophy of the parkinsonian subtype (abstract). Mov. Disord. 2012, 27(Suppl. 1):1182.
134. Probst-Cousin S., Rickert C.H., Schmid K.W., Gullotta F. Cell death mechanisms in multiple system atrophy. J. Neuropathol. Exp. Neurol. 1998, 57:814-821.
135. Puschban Z., Scherfler C., Granata R., Laboyrie P., Quinn N.P., Jenner P., Poewe W., Wenning G.K. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts. Neuroscience 2000, 95:377-388.
136. Puschban Z., Waldner R., Seppi K., Stefanova N., Humpel C., Scherfler C., Levivier M., Poewe W., Wenning G.K. Failure of neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy). Exp. Neurol. 2000, 164:166-175.
137. Quinn N., Barker R.A., Wenning G.K. Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective?. Clin. Pharmacol. Ther. 2008, 83:663-665.
138. Raffel D.M., Koeppe R.A., Little R., Wang C.N., Liu S., Junck L., Heumann M., Gilman S. PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J. Nucl. Med. 2006, 47:1769-1777.
139. Reynolds A.D., Kadiu I., Garg S.K., Glanzer J.G., Nordgren T., Ciborowski P., Banerjee R., Gendelman H.E. Nitrated alpha-synuclein and microglial neuroregulatory activities. J. Neuroimmune Pharmacol. 2008, 3:59-74.
140. Riedel M., Goldbaum O., Richter-Landsberg C. Alpha-synuclein promotes the recruitment of tau to protein inclusions in oligodendroglial cells: effects of oxidative and proteolytic stress. J. Mol. Neurosci. 2009, 39:226-234.
141. Rockenstein E., Ubhi K., Inglis C., Mante M., Patrick C., Adame A., Masliah E. Neuronal to oligodendroglial alpha-synuclein redistribution in a double transgenic model of multiple system atrophy. Neuroreport 2012, 23:259-264.
142. Rojo A.I., Innamorato N.G., Martin-Moreno A.M., De Ceballos M.L., Yamamoto M., Cuadrado A. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 2010, 58:588-598.
143. Sacca F., Marsili A., Quarantelli M., Brescia Morra V., Brunetti A., Carbone R., Pane C., Puorro G., Russo C.V., Salvatore E., Tucci T., De Michele G., Filla A. A randomized clinical trial of lithium in multiple system atrophy. J. Neurol. 2013, 260:458-461.
144. Sailer A., on behalf of the MSA GWAS Consortium First genome-wide association study in multiple system atrophy (abstract). Mov. Disord. 2012, 27(Suppl. 1):1425.
145. Sato H., Kato T., Arawaka S. The role of Ser129 phosphorylation of alpha-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models. Rev. Neurosci. 2013, 24:115-123.
146. Scherfler C., Puschban Z., Ghorayeb I., Goebel G.P., Tison F., Jellinger K., Poewe W., Wenning G.K. Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). Neuroscience 2000, 99:43-54.
147. Scherfler C., Sather T., Diguet E., Stefanova N., Puschban Z., Tison F., Poewe W., Wenning G.K. Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (Parkinson variant of multiple system atrophy). J. Neural Transm. 2005, 112:1025-1033.
148. Scholz S.W., Houlden H., Schulte C., Sharma M., Li A., Berg D., Melchers A., Paudel R., Gibbs J.R., Simon-Sanchez J., Paisan-Ruiz C., Bras J., Ding J., Chen H., Traynor B.J., Arepalli S., Zonozi R.R., Revesz T., Holton J., Wood N., Lees A., Oertel W., Wullner U., Goldwurm S., Pellecchia M.T., Illig T., Riess O., Fernandez H.H., Rodriguez R.L., Okun M.S., Poewe W., Wenning G.K., Hardy J.A., Singleton A.B., Gasser T. SNCA variants are associated with increased risk for multiple system atrophy. Ann. Neurol. 2009, 65:610-614.
149. Shi M., Zabetian C.P., Hancock A.M., Ginghina C., Hong Z., Yearout D., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Leverenz J.B., Zhang J. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci. Lett. 2010, 480:78-82.
150. Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Kim H.M., Leverenz J.B., Montine T.J., Ginghina C., Kang U.J., Cain K.C., Wang Y., Aasly J., Goldstein D., Zhang J. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011, 69:570-580.
151. Shoulson I. Experimental therapeutics of neurodegenerative disorders: unmet needs. Science 1998, 282:1072-1074.
152. Shults C.W., Rockenstein E., Crews L., Adame A., Mante M., Larrea G., Hashimoto M., Song D., Iwatsubo T., Tsuboi K., Masliah E. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J. Neurosci. 2005, 25:10689-10699.
153. Soma H., Yabe I., Takei A., Fujiki N., Yanagihara T., Sasaki H. Associations between multiple system atrophy and polymorphisms of SLC1A4, SQSTM1, and EIF4EBP1 genes. Mov. Disord. 2008, 23:1161-1167.
154. Song Y.J., Lundvig D.M., Huang Y., Gai W.P., Blumbergs P.C., Hojrup P., Otzen D., Halliday G.M., Jensen P.H. p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am. J. Pathol. 2007, 171:1291-1303.
155. Spillantini M.G., Crowther R.A., Jakes R., Cairns N.J., Lantos P.L., Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 1998, 251:205-208.
156. Stefanova N., Puschban Z., Fernagut P.O., Brouillet E., Tison F., Reindl M., Jellinger K.A., Poewe W., Wenning G.K. Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). Acta Neuropathol. 2003, 106:157-166.
157. Stefanova N., Mitschnigg M., Ghorayeb I., Diguet E., Geser F., Tison F., Poewe W., Wenning G.K. Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. J. Neurosci. Res. 2004, 78:87-91.
158. Stefanova N., Reindl M., Neumann M., Haass C., Poewe W., Kahle P.J., Wenning G.K. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am. J. Pathol. 2005, 166:869-876.
159. Stefanova N., Reindl M., Neumann M., Kahle P.J., Poewe W., Wenning G.K. Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov. Disord. 2007, 22:2196-2203.
160. Stefanova N., Poewe W., Wenning G.K. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp. Neurol. 2008, 210:421-427.
161. Stefanova N., Bucke P., Duerr S., Wenning G.K. Multiple system atrophy: an update. Lancet Neurol. 2009, 8:1172-1178.
162. Stefanova N., Hainzer M., Stemberger S., Couillard-Despres S., Aigner L., Poewe W., Wenning G.K. Striatal transplantation for multiple system atrophy - are grafts affected by alpha-synucleinopathy?. Exp. Neurol. 2009, 219:368-371.
163. Stefanova N., Fellner L., Reindl M., Masliah E., Poewe W., Wenning G.K. Toll-like receptor 4 promotes alpha-synuclein clearance and survival of nigral dopaminergic neurons. Am. J. Pathol. 2011, 179:954-963.
164. Stefanova N., Georgievska B., Eriksson H., Poewe W., Wenning G.K. Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Neurotox. Res. 2012, 21:393-404.
165. Steiner J.A., Angot E., Brundin P. A deadly spread: cellular mechanisms of alpha-synuclein transfer. Cell Death Differ. 2011, 18:1425-1433.
166. Stemberger S., Poewe W., Wenning G.K., Stefanova N. Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. Exp. Neurol. 2010, 224:459-464.
167. Stemberger S., Jamnig A., Stefanova N., Lepperdinger G., Reindl M., Wenning G.K. Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and neuroprotection. PLoS ONE 2011, 6:e19808.
168. Stemberger S., Scholz S.W., Singleton A.B., Wenning G.K. Genetic players in multiple system atrophy: unfolding the nature of the beast. Neurobiol. Aging 2011, 32:1924.e5-1924.e14.
169. Storch A., Csoti I., Eggert K., Henriksen T., Plate A., Lorrain M., Oertel W.H., Antonini A. Intrathecal application of autologous bone marrow cell preparations in parkinsonian syndromes. Mov. Disord. 2012, 27:1552-1555.
170. Storey E., Hyman B.T., Jenkins B., Brouillet E., Miller J.M., Rosen B.R., Beal M.F. 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J. Neurochem. 1992, 58:1975-1978.
171. Streit W.J., Mrak R.E., Griffin W.S. Microglia and neuroinflammation: a pathological perspective. J. Neuroinflamm. 2004, 1:14.
172. Su M., Shi J.J., Yang Y.P., Li J., Zhang Y.L., Chen J., Hu L.F., Liu C.F. HDAC6 regulates aggresome-autophagy degradation pathway of alpha-synuclein in response to MPP+-induced stress. J. Neurochem. 2011, 117:112-120.
173. Su X., Maguire-Zeiss K.A., Giuliano R., Prifti L., Venkatesh K., Federoff H.J. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging 2008, 29:1690-1701.
174. Su X., Federoff H.J., Maguire-Zeiss K.A. Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox. Res. 2009, 16:238-254.
175. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
176. Takahashi M., Tomizawa K., Ishiguro K., Sato K., Omori A., Sato S., Shiratsuchi A., Uchida T., Imahori K. A novel brain-specific 25kDa protein (p25) is phosphorylated by a Ser/Thr-Pro kinase (TPK II) from tau protein kinase fractions. FEBS Lett. 1991, 289:37-43.
177. The Multiple-System Atrophy Research Collaboration Mutations in COQ2 in familial and sporadic multiple-system atrophy. N. Engl. J. Med. 2013, 369:233-244.
178. Trojanowski J.Q., Revesz T. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol. Appl. Neurobiol. 2007, 33:615-620.
179. Tu P.H., Galvin J.E., Baba M., Giasson B., Tomita T., Leight S., Nakajo S., Iwatsubo T., Trojanowski J.Q., Lee V.M. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol. 1998, 44:415-422.
180. Ubhi K., Rockenstein E., Mante M., Patrick C., Adame A., Thukral M., Shults C., Masliah E. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 2008, 19:1271-1276.
181. Ubhi K., Lee P.H., Adame A., Inglis C., Mante M., Rockenstein E., Stefanova N., Wenning G.K., Masliah E. Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. J. Neurosci. Res. 2009, 87:2728-2739.
182. Ubhi K., Rockenstein E., Mante M., Inglis C., Adame A., Patrick C., Masliah E. Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophy. Neuroreport 2010, 21:457-462.
183. Ubhi K., Rockenstein E., Mante M., Inglis C., Adame A., Patrick C., Whitney K., Masliah E. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J. Neurosci. 2010, 30:6236-6246.
184. Ubhi K., Low P., Masliah E. Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci. 2011, 34:581-590.
185. Ubhi K., Inglis C., Mante M., Patrick C., Adame A., Spencer B., Rockenstein E., May V., Winkler J., Masliah E. Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of alpha-synucleinopathy. Exp. Neurol. 2012, 234:405-416.
186. Ubhi K., Rockenstein E., Kragh C., Inglis C., Spencer B., Michael S., Mante M., Adame A., Galasko D., Masliah E. Widespread microRNA dysregulation in multiple system atrophy - disease-related alteration in miR-96. Eur. J. Neurosci. 2013, 1-16. 10.1111/ejn.12444.
187. Valera E., Ubhi K., Mante M., Rockenstein E., Masliah E. Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy. Glia 2013, 62:317-337.
188. Vanacore N., Bonifati V., Fabbrini G., Colosimo C., Marconi R., Nicholl D., Bonuccelli U., Stocchi F., Lamberti P., Volpe G., De Michele G., Iavarone I., Bennett P., Vieregge P., Meco G. Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms. Neurology 2000, 54:114-119.
189. Venero J.L., Romero-Ramos M., Revuelta M., Machado A., Cano J. Intrastriatal quinolinic acid injections protect against 6-hydroxydopamine-induced lesions of the dopaminergic nigrostriatal system. Brain Res. 1995, 672:153-158.
190. Vidal J.S., Vidailhet M., Elbaz A., Derkinderen P., Tzourio C., Alperovitch A. Risk factors of multiple system atrophy: a case-control study in French patients. Mov. Disord. 2008, 23:797-803.
191. Wakabayashi K., Ikeuchi T., Ishikawa A., Takahashi H. Multiple system atrophy with severe involvement of the motor cortical areas and cerebral white matter. J. Neurol. Sci. 1998, 156:114-117.
192. Wakabayashi K., Mori F., Tanji K., Orimo S., Takahashi H. Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. Acta Neuropathol. 2010, 120:1-12.
193. Waldner R., Puschban Z., Scherfler C., Seppi K., Jellinger K., Poewe W., Wenning G.K. No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy). Neuroscience 2001, 102:581-592.
194. Walker L.C., Diamond M.I., Duff K.E., Hyman B.T. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. 2013, 70:304-310.
195. Wang Y., Shi M., Chung K.A., Zabetian C.P., Leverenz J.B., Berg D., Srulijes K., Trojanowski J.Q., Lee V.M., Siderowf A.D., Hurtig H., Litvan I., Schiess M.C., Peskind E.R., Masuda M., Hasegawa M., Lin X., Pan C., Galasko D., Goldstein D.S., Jensen P.H., Yang H., Cain K.C., Zhang J. Phosphorylated alpha-synuclein in Parkinson's disease. Sci. Transl. Med. 2012, 4:121ra120.
196. Watanabe H., Saito Y., Terao S., Ando T., Kachi T., Mukai E., Aiba I., Abe Y., Tamakoshi A., Doyu M., Hirayama M., Sobue G. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002, 125:1070-1083.
197. Watts J.C., Giles K., Oehler A., Middleton L., Dexter D.T., Gentleman S.M., Dearmond S.J., Prusiner S.B. Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:19555-19560.
198. Wenning G.K., Ben Shlomo Y., Magalhaes M., Daniel S.E., Quinn N.P. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994, 117(Pt 4):835-845.
199. Wenning G.K., Quinn N., Magalhaes M., Mathias C., Daniel S.E. Minimal change multiple system atrophy. Mov. Disord. 1994, 9:161-166.
200. Wenning G.K., Granata R., Laboyrie P.M., Quinn N.P., Jenner P., Marsden C.D. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration. Mov. Disord. 1996, 11:522-532.
201. Wenning G.K., Tison F., Elliott L., Quinn N.P., Daniel S.E. Olivopontocerebellar pathology in multiple system atrophy. Mov. Disord. 1996, 11:157-162.
202. Wenning G.K., Jellinger K.A. The role of alpha-synuclein in the pathogenesis of multiple system atrophy. Acta Neuropathol. 2005, 109:129-140.
203. Wenning G.K., Stefanova N., Jellinger K.A., Poewe W., Schlossmacher M.G. Multiple system atrophy: a primary oligodendrogliopathy. Ann. Neurol. 2008, 64:239-246.
204. Wenning G.K., Stefanova N. Recent developments in multiple system atrophy. J. Neurol. 2009, 256:1791-1808.
205. Wenning G.K., Geser F., Krismer F., Seppi K., Duerr S., Boesch S., Kollensperger M., Goebel G., Pfeiffer K.P., Barone P., Pellecchia M.T., Quinn N.P., Koukouni V., Fowler C.J., Schrag A., Mathias C.J., Giladi N., Gurevich T., Dupont E., Ostergaard K., Nilsson C.F., Widner H., Oertel W., Eggert K.M., Albanese A., del Sorbo F., Tolosa E., Cardozo A., Deuschl G., Hellriegel H., Klockgether T., Dodel R., Sampaio C., Coelho M., Djaldetti R., Melamed E., Gasser T., Kamm C., Meco G., Colosimo C., Rascol O., Meissner W.G., Tison F., Poewe W. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 2013, 12:264-274.
206. Wenning G., Krismer F., Poewe W. Rifampicin for multiple system atrophy. Lancet Neurol. 2014, 13:237-239.
207. Wilkins A., Chandran S., Compston A. A role for oligodendrocyte-derived IGF-1 in trophic support of cortical neurons. Glia 2001, 36:48-57.
208. Wilkins A., Majed H., Layfield R., Compston A., Chandran S. Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor. J. Neurosci. 2003, 23:4967-4974.
209. Winner B., Jappelli R., Maji S.K., Desplats P.A., Boyer L., Aigner S., Hetzer C., Loher T., Vilar M., Campioni S., Tzitzilonis C., Soragni A., Jessberger S., Mira H., Consiglio A., Pham E., Masliah E., Gage F.H., Riek R. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4194-4199.
210. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 2002, 22:1763-1771.
211. Wullner U., Abele M., Schmitz-Huebsch T., Wilhelm K., Benecke R., Deuschl G., Klockgether T. Probable multiple system atrophy in a German family. J. Neurol. Neurosurg. Psychiatry 2004, 75:924-925.
212. Wullner U., Schmitz-Hubsch T., Abele M., Antony G., Bauer P., Eggert K. Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson's disease. J. Neural Transm. 2007, 114:1161-1165.
213. Xie W., Wan O.W., Chung K.K. New insights into the role of mitochondrial dysfunction and protein aggregation in Parkinson's disease. Biochim. Biophys. Acta 2010, 1802:935-941.
214. Yazawa I., Giasson B.I., Sasaki R., Zhang B., Joyce S., Uryu K., Trojanowski J.Q., Lee V.M. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005, 45:847-859.
215. Zuscik M.J., Sands S., Ross S.A., Waugh D.J., Gaivin R.J., Morilak D., Perez D.M. Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. Nat. Med. 2000, 6:1388-1394.